Two Astrazeneca breast cancer projects record apparent pivotal successes in settings where Roche had failed.
Key upcoming clinical results approach in the third quarter for lecanemab, high-dose Eylea and Zimura.
All-comer Serd studies in pretreated breast cancer look doomed, so why do Astra and Lilly persist? And why isn’t Radius seizing its advantage?
Amcenestrant flunks the long-delayed Ameera-3 trial in ER-positive Her2-negative breast cancer, so how much blame can be put on poor study design?
The company’s androgen receptor degrader might have a pathway to approval, but the potential market looks small.
But the pace of biopharma asset deals dips. Are the two trends related?
This year has yet to see a blockbuster-style deal, but prices remain punchy nevertheless.